MD
Mittie Doyle
Chief Medical Officer

Mittie Doyle insider trades: Avalo Therapeutics (AVTX) stock sales

Chief Medical Officer, Avalo Therapeutics Last trade Aug 28, 2026 18 Form 4 filings
$2.8M
Sold, last 12 months
8 sales
$0
Bought, last 12 months
0 buys
8
Open-market trades
since 2026
3
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Mittie reports to the SEC

Open-market buys and sales

8 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 28, 2026AVTX↓ Sell$14K
Aug 17, 2026AVTX↓ Sell$20K
Aug 10, 2026AVTX↓ Sell$14K
May 15, 2026AVTX↓ Sell$56K
May 6, 2026AVTX↓ Sell$2.2M
Apr 6, 2026AVTX↓ Sell$72K
Apr 1, 2026AVTX↓ Sell$11K
Mar 16, 2026AVTX↓ Sell$412K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other AVTX insiders

Open-market trades in the last 12 months

About Mittie Doyle's insider trades

Mittie Doyle is Chief Medical Officer at Avalo Therapeutics (AVTX). Since Mar 16, 2026, Mittie has reported no open-market purchases and 8 sales worth $2.8M on SEC Form 4. In the last 12 months: 8 sales ($2.8M).

Their filings also include option exercises (8 filings), grants and awards (7 filings), shares withheld for taxes (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AVTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.